A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
Not yet recruiting · NCT05896371 · Registry updated 2025-03-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, cancer, male reproductive organ cancer, male reproductive system disorder, metastatic malignant neoplasm, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-03-30 | NCT05896371 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Institutes of Health Research (CIHR) | 339 |
| CHU de Quebec-Universite Laval | 54 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||